Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada
Background
In patients undergoing cardiac rhythm device surgery, it is common practice to discontinue oral anticoagulation and to perform heparin bridging in order to reduce the risk of bleeding and minimize the risk of thromboembolic events.
Objective
The purpose of this study was to determine the perioperative anticoagulation strategies currently in use.
Methods
A survey presented four clinical scenarios of patients on oral anticoagulation undergoing cardiac rhythm device surgery. The scenarios represented a gradient of perceived thromboembolic risk based on the presence of atrial fibrillation, a mechanical heart valve, previous stroke, and the remainder of the CHADS2 risk factors (congestive heart failure, hypertension, age >75 years, diabetes, previous stroke or transient ischemic attack). Respondents were offered six options that included discontinuing oral anticoagulation without heparin, three different heparin bridging protocols, and ongoing oral anticoagulation with reduced or therapeutic dose warfarin.
Results
Based on responses from 38 (61%) of 62 electrophysiologists surveyed across Canada, 83% of respondents held warfarin without bridging in a low-risk, 78-year-old patient with atrial fibrillation (CHADS2 score 1). In three higher-risk patient scenarios, 67% to 100% of respondents chose heparin bridging or ongoing warfarin; 38% to 72% of respondents chose heparin bridging, with 23% to 36% choosing variable use of ongoing warfarin. In all three cases where respondents indicated that they would bridge, each of the three heparin regimens was chosen by at least 20% of respondents.
Conclusion
There is a wide range of approaches to perioperative management in patients on oral anticoagulation undergoing cardiac rhythm device surgery. Clinical equipoise is evident and supports the need for comparative studies.
Keywords: Anticoagulation, Pacemaker, Bridging, Heparin
To access this article, please choose from the options below
Dr. Krahn is a Career Investigator of the Heart and Stroke Foundation of Ontario and is supported by a grant from the Heart and Stroke Foundation of Ontario (NA3397). Dr. Essebag is the recipient of a Clinician Scientist Award from the Canadian Institutes of Health Research.
PII: S1547-5271(09)00576-1
doi:10.1016/j.hrthm.2009.05.027
© 2009 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
